RCS - Tristel PLC - Study shows Tristel Wipes System benefits <Origin Href="QuoteRef">TSTL.L</Origin>

TristelAnnouncement

11/10/2016 07:06

RNS Number : 1596M
Tristel PLC
11 October 2016
Tristel plc
("Tristel" or "the Company")
Comparison of high-level disinfectants for flexible nasendoscopes published in
The Journal of Laryngology & Otology
Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that in a randomised, single-blind comparison of disinfectants used in Ear, Nose and Threat clinics, its Wipes System proved to be the equal in terms of microbiological efficacy to disinfectants produced by Du Pont and Johnson & Johnson. In the study Du Pont's PeraSafe peracetic acid disinfectant was used in a tray, and Johnson & Johnson's Cidex OPA ortho phthalaldehyde disinfectant was used in an automated washer-disinfector manufactured by Medvators Inc. The Tristel Wipes System is a stand-alone process requiring no equipment, support building services, or maintenance. The study concluded that the Wipes System has no capital outlay cost, the lowest running cost, the greatest convenience, and the fastest turnaround time for medical instruments of the three products evaluated. 
The study, which was conducted by the Bay of Plenty District Health Board, Tauranga, New Zealand in 2011 has been published in the The Journal of Laryngology & Otology [Hitchcock, B., Moynan, S., Frampton, C., Reuther, R., Gilling, P. and Rowe, F. (2016) 'A randomised, single-blind comparison of high-level disinfectants for flexible nasendoscopes', The Journal of Laryngology Otology, pp. 1-7. doi: 10.1017/S0022215116008860]. Preliminary results of the study were presented at the 11th Congress for German Hospital Hygiene held in Berlin in March 2012, and reported by an RNS Reach on 29 March 2012.
The Tristel Wipes System is a unique, patented decontamination method for non-lumened scopes and probes. It has been a very significant sales success for the Company globally. Worldwide sales in the financial year ending June 2012 were 3.3m and are expected to be 8.7m in the year ending June 2016. 
Paul Swinney, CEO, comments:"We are pleased to see at long last the publication in a peer-reviewed journal of this significant study comparing our Wipes System with competitor products manufactured by two of the world's major infection prevention companies. The results affirm the key advantages of our Wipes over alternative chemistries and disinfection methods. This is the twenty-fifth peer-reviewed and published scientific paper featuring Tristel products - a body of evidence of our products' attributes that forms one of our Company's key strengths."
For further information please contact:
Tristel plc
Tel: 01638 721 500
Paul Swinney, Chief Executive Officer
Liz Dixon, Finance Director
Walbrook PR Ltd
Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus
Mob: 07980 541 893
Lianne Cawthorne
Mob: 07584 391 303
finnCap
Tel: 020 7600 1658
Geoff Nash/ Giles Rolls (Corporate Finance)
Stephen Norcross (Corporate Broking)

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAAKKDQPBDDKKD